Pains and Gains from China’s Experiences with Emerging Epidemics: From SARS to H7N9

• Published in: BioMed Research International
• Main Authors: Pengfei Wei, Zelang Cai, Jinwen Hua, Weijia Yu, Jiajie Chen, Kang Kang, Congling Qiu, Lanlan Ye, Jiayun Hu, Kunmei Ji
• Format: Article in Journal/Newspaper
• Language: English
• Published: Hindawi Limited 2016
• Subjects: Medicine; R; Avian flu
• Online Access: https://doi.org/10.1155/2016/5717108; https://doaj.org/article/2b8699feecee42a78aafa2acc4d66b87

Over the recent decades, China experienced several emerging virus outbreaks including those caused by the severe acute respiratory syndrome- (SARS-) coronavirus (Cov), H5N1 virus, and H7N9 virus. The SARS tragedy revealed faults in China’s infectious disease prevention system, propelling the Chinese government to enact reforms that enabled better combating of the subsequent H1N1 and H7N9 avian flu epidemics. The system is buttressed by three fundamental, mutually reinforcing components: (1) enduring government administration reforms, including legislation establishing a unified public health emergency management system; (2) prioritized funding for biotechnology and biomedicine industrialization, especially in the areas of pathogen identification, drug production, and the development of vaccines and diagnostics; and (3) increasing investment for public health and establishment of a rapid-response infectious diseases prevention and control system. China is now using its hard-gained experience to support the fight against Ebola in Africa and the Middle East Respiratory Syndrome in its own country.